Compare SBCF & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBCF | SUPN |
|---|---|---|
| Founded | 1926 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2009 | 2010 |
| Metric | SBCF | SUPN |
|---|---|---|
| Price | $35.57 | $47.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $38.00 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.0M | 909.0K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 10.56 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $45.04 | $22.70 |
| Revenue Next Year | $6.30 | $19.14 |
| P/E Ratio | $42.11 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.96 | $41.76 |
| 52 Week High | $35.64 | $59.68 |
| Indicator | SBCF | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 67.00 | 51.05 |
| Support Level | $31.01 | $43.27 |
| Resistance Level | N/A | $47.55 |
| Average True Range (ATR) | 0.86 | 2.50 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 97.87 | 43.60 |
Seacoast Banking Corp of Florida is a holding company. The company provides integrated financial services, including commercial and consumer banking, wealth management, and mortgage and insurance services, to customers across Florida through branch, mobile, and online banking solutions. It maintains day-to-day operations, particularly in the areas of operations, treasury management systems, information technology, and security. The company has one reportable segment that provides these integrated financial services, with segment revenues driven mainly by interest and fees on loans, interest on cash and cash equivalents, and investment securities, and fees on depository products and services.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.